Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 7/2018

13.09.2017 | Originalie

Influence of the MIF polymorphism −173G > C on Turkish postmenopausal women with osteoporosis

verfasst von: A. Z. Ozsoy, N. Karakus, S. Tural, S. Yigit, N. Kara, G. Alayli, M. K. Tumer, O. Kuru

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

MIF, a proinflammatory cytokine, contributes to the pathogenesis of acute, chronic, and autoimmune inflammatory disorders and balances the suppressive effect of glucocorticoids on the immune system. There is an interaction between bone metabolism and the immune system via the production of cytokines. We aimed to analyze the relationship between the MIF gene −173G > C promoter polymorphism and osteoporosis.

Methods

In this case–control study performed in a university hospital, 286 samples (136 women with osteoporosis and 150 healthy age-matched controls) participated. The polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) assay was used to genotype the MIF gene polymorphism. The alleles and genotypes frequencies of patients and controls were compared using the χ2 test.

Results

The genotype frequencies of MIF gene −173G > C polymorphism showed statistically significant differences between patients and controls (p = 0.038). Also, the subjects carrying the variant C allele in the MIF −173 position were at significantly higher risk of osteoporosis than subjects carrying the wild-type G allele (p = 0.009, odds ratio 1.7, 95% confidence interval 1.1–2.6).

Conclusion

Our study suggested a strong association between MIF gene −173G > C polymorphism and osteoporosis in a Turkish population.
Literatur
1.
Zurück zum Zitat Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos 7:3–20CrossRefPubMedPubMedCentral Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos 7:3–20CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304CrossRefPubMed Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304CrossRefPubMed
3.
Zurück zum Zitat Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T (1985) Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 135:2562–2568PubMed Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T (1985) Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 135:2562–2568PubMed
4.
Zurück zum Zitat Takayanagi H, Ogasawara K, Hida S et al (2000) T‑cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605CrossRefPubMed Takayanagi H, Ogasawara K, Hida S et al (2000) T‑cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605CrossRefPubMed
5.
Zurück zum Zitat Calandra T, Bucala R (1995) Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47:39–51PubMed Calandra T, Bucala R (1995) Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47:39–51PubMed
6.
Zurück zum Zitat Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518CrossRefPubMed Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518CrossRefPubMed
7.
Zurück zum Zitat Onodera S, Nishihira J, Iwabuchi K et al (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts.Relevance to intracellular signaling pathways. J Biol Chem 277:7865–7874CrossRefPubMed Onodera S, Nishihira J, Iwabuchi K et al (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts.Relevance to intracellular signaling pathways. J Biol Chem 277:7865–7874CrossRefPubMed
8.
Zurück zum Zitat Onodera S, Sasaki S, Ohshima S et al (2006) Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 21:876–885CrossRefPubMed Onodera S, Sasaki S, Ohshima S et al (2006) Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 21:876–885CrossRefPubMed
9.
Zurück zum Zitat Oshima S, Onodera S, Amizuka N et al (2006) Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomyinduced bone loss. FEBS Lett 580:1251–1256CrossRefPubMed Oshima S, Onodera S, Amizuka N et al (2006) Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomyinduced bone loss. FEBS Lett 580:1251–1256CrossRefPubMed
10.
Zurück zum Zitat Onodera S, Nishihira J, Yamazaki M, Ishibashi T, Minami A (2004) Increased expression of macrophage migration inhibitory factor during fracture healing in rats. Histochem Cell Biol 121:209–217CrossRefPubMed Onodera S, Nishihira J, Yamazaki M, Ishibashi T, Minami A (2004) Increased expression of macrophage migration inhibitory factor during fracture healing in rats. Histochem Cell Biol 121:209–217CrossRefPubMed
11.
Zurück zum Zitat Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence ofproinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608CrossRefPubMed Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence ofproinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608CrossRefPubMed
12.
Zurück zum Zitat Meazza C, Travaglino P, Pignatti P et al (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:232–237CrossRefPubMed Meazza C, Travaglino P, Pignatti P et al (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:232–237CrossRefPubMed
13.
Zurück zum Zitat Onodera S, Tanji H, Suzuki K et al (1999) High expression ofmacrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11:163–167CrossRefPubMed Onodera S, Tanji H, Suzuki K et al (1999) High expression ofmacrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11:163–167CrossRefPubMed
14.
Zurück zum Zitat Donn R, Alourfi Z, De Benedetti F et al (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409CrossRefPubMed Donn R, Alourfi Z, De Benedetti F et al (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409CrossRefPubMed
15.
Zurück zum Zitat Baugh JA, Chitnis S, Donnelly SC et al (2002) Functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) geneassociated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176CrossRefPubMed Baugh JA, Chitnis S, Donnelly SC et al (2002) Functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) geneassociated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176CrossRefPubMed
16.
Zurück zum Zitat Renner P, Roger T, Calandra T (2005) Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41(Suppl 7):513–519CrossRef Renner P, Roger T, Calandra T (2005) Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41(Suppl 7):513–519CrossRef
17.
Zurück zum Zitat Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029CrossRefPubMed Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029CrossRefPubMed
18.
Zurück zum Zitat Bucala R (2006) MIF and the Genetic Basis of Macrophage Responsiveness. Curr Immunol Rev 2:217-223CrossRef Bucala R (2006) MIF and the Genetic Basis of Macrophage Responsiveness. Curr Immunol Rev 2:217-223CrossRef
19.
Zurück zum Zitat Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176CrossRefPubMed Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176CrossRefPubMed
20.
Zurück zum Zitat World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group (1994) Organization Technical Report Series. World Health 843:1–129 World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group (1994) Organization Technical Report Series. World Health 843:1–129
21.
Zurück zum Zitat Wang FF, Huang XF, Shen N et al (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 15(3):R65 Wang FF, Huang XF, Shen N et al (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 15(3):R65
22.
Zurück zum Zitat Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800CrossRefPubMed Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800CrossRefPubMed
23.
Zurück zum Zitat Gregory JL, Morand EF, Mckeown SJ et al (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072–8079CrossRefPubMed Gregory JL, Morand EF, Mckeown SJ et al (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072–8079CrossRefPubMed
24.
Zurück zum Zitat Morand EF, Leech M, Bemhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399–410CrossRefPubMed Morand EF, Leech M, Bemhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399–410CrossRefPubMed
25.
Zurück zum Zitat Tillmann S, Bernhagen J, Noels H (2013) Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol 16:115 Tillmann S, Bernhagen J, Noels H (2013) Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol 16:115
26.
Zurück zum Zitat Makino A, Nakamura T, Hirano M et al (2010) High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213:573–578CrossRefPubMed Makino A, Nakamura T, Hirano M et al (2010) High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213:573–578CrossRefPubMed
27.
Zurück zum Zitat Ma L, Xue HB, Guan XH et al (2013) Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and anctvity in vitiligo vulgaris. Braz J Med Biol Res 46:460–464CrossRefPubMedPubMedCentral Ma L, Xue HB, Guan XH et al (2013) Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and anctvity in vitiligo vulgaris. Braz J Med Biol Res 46:460–464CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Swanberg M, McGuigan F, Ivaska KK et al (2010) Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women. Bone 47(2):424–429CrossRefPubMedPubMedCentral Swanberg M, McGuigan F, Ivaska KK et al (2010) Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women. Bone 47(2):424–429CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Martínez A, Orozco G, Varadé J, López MS et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747CrossRefPubMed Martínez A, Orozco G, Varadé J, López MS et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747CrossRefPubMed
30.
Zurück zum Zitat Barton A, Lamb R, Symmons D et al (2003) Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 4:487–491CrossRefPubMed Barton A, Lamb R, Symmons D et al (2003) Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 4:487–491CrossRefPubMed
Metadaten
Titel
Influence of the MIF polymorphism −173G > C on Turkish postmenopausal women with osteoporosis
verfasst von
A. Z. Ozsoy
N. Karakus
S. Tural
S. Yigit
N. Kara
G. Alayli
M. K. Tumer
O. Kuru
Publikationsdatum
13.09.2017
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 7/2018
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-017-0382-5

Weitere Artikel der Ausgabe 7/2018

Zeitschrift für Rheumatologie 7/2018 Zur Ausgabe

Mitteilungen der DRL

Anruf beim Rheumafoon genügt

DGRh Mitgliedsantrag

DGRh Mitgliedsantrag

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.